How does 0RNL's PS Ratio compare to its peers?

0RNL is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (6.6x).

How does 0RNL's PS Ratio compare vs other companies in the GB Biotechs Industry?

0RNL is good value based on its Price-To-Sales Ratio (0.4x) compared to the UK Biotechs industry average (21.2x)

What is 0RNL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 0RNL's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of 0RNL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 0RNL's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Lysogene (LSE:0RNL) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

0RNL Stock Overview

Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. More details

0RNL fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings have grown 14.6% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Has less than 1 year of cash runway

Does not have a meaningful market cap (€5M)

Shareholders have been diluted in the past year

+ 1 more risk

Lysogene S.A. Competitors

Genflow Biosciences

LSE:GENF

UK£6.3m

Aptamer Group

AIM:APTA

UK£5.3m

ProBiotix Health

OFEX:PBX

UK£10.7m

Roquefort Therapeutics

LSE:ROQ

UK£5.0m

Price History & Performance

Summary of all time highs, changes and price drops for Lysogene
Historical stock prices
Current Share Price	€0.40
52 Week High	€1.15
52 Week Low	€0.40
Beta	0.89
11 Month Change	0%
3 Month Change	n/a
1 Year Change	-61.39%
33 Year Change	n/a
5 Year Change	-88.54%
Change since IPO	-91.29%

Recent updates

Shareholder Returns

	0RNL	GB Biotechs	GB Market
7D	0%	-1.7%	-1.0%
1Y	-61.4%	-19.2%	6.9%

Return vs Industry: 0RNL underperformed the UK Biotechs industry which returned -15.4% over the past year.

Return vs Market: 0RNL underperformed the UK Market which returned 1.4% over the past year.

Price Volatility

Is 0RNL's price volatile compared to industry and market?
0RNL volatility
0RNL Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.1%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0RNL has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0RNL's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	22	Karen Pignet-Aiach	www.lysogene.com

Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a research collaboration with the Yeda Research and Development Co Ltd.

Lysogene S.A. Fundamentals Summary

How do Lysogene's earnings and revenue compare to its market cap?
0RNL fundamental statistics
Market cap	€4.95m
Earnings (TTM)	-€7.37m
Revenue (TTM)	€12.77m

0.4x

P/S Ratio

-0.7x

P/E Ratio

Is 0RNL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RNL income statement (TTM)
Revenue	€12.77m
Cost of Revenue	€0
Gross Profit	€12.77m
Other Expenses	€20.14m
Earnings	-€7.37m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.42
Gross Margin	100.00%
Net Profit Margin	-57.76%
Debt/Equity Ratio	-402.9%

How did 0RNL perform over the long term?

See historical performance and comparison

This company listing is no longer active

0RNL Stock Overview

Rewards

Risk Analysis

Lysogene S.A. Competitors

LSE:GENF

UK£6.3m

AIM:APTA

UK£5.3m

OFEX:PBX

UK£10.7m

LSE:ROQ

UK£5.0m

Price History & Performance

Recent News & Updates

Lysogene Announces to Delist from Euronext

Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer

Lysogene Provides Updates and Topline Results from Phase 2/3 Aavance Gene Therapy Clinical Study

First half 2022 earnings released: EPS: €0.04 (vs €0.33 loss in 1H 2021)

Lysogene Announces New Board of Directors

Lysogene Provides Additional Update on Aavance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in Children with MMPS IIIA

Recent updates

Lysogene Announces to Delist from Euronext

Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer

Lysogene Provides Updates and Topline Results from Phase 2/3 Aavance Gene Therapy Clinical Study

First half 2022 earnings released: EPS: €0.04 (vs €0.33 loss in 1H 2021)

Lysogene Announces New Board of Directors

Lysogene Provides Additional Update on Aavance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in Children with MMPS IIIA

Lysogene S.A. Provides Clinical Update on AAvance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA At the 25Th Annual ASGCT Meeting

Full year 2021 earnings released: €0.81 loss per share (vs €0.32 loss in FY 2020)

Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of Mpsiiia

Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101

Lysogene S.A. Provides Medical Update

Lysogene S.A. announced that it has received €4.3 million in funding from Bpifrance Investissement SAS

First half 2021 earnings released: €0.33 loss per share (vs €0.015 profit in 1H 2020)

Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis

Forecast to breakeven in 2022

Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis

Lysogene Announces Phase 3 Gene Therapy Platform Company Targeting Central Nervous System Diseases

Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium 2021

Lysogene S.A. Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with Lys-Gm101 for the Treatment of Gm1 Gangliosidosis

Lysogene S.A., Annual General Meeting, Jun 25, 2021

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis